

Switch from EFV plus ABC-3TC to EFV-TDF-FTC
ROCKET-1 Trial

Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Design

Study Design: ROCKET Study

- **Background:** Randomized, open label, phase 4 trial to assess the effect on lipid profile of switching from EFV plus ABC-3TC to EFV-TDF-FTC in hypercholesterolemic adults with HIV
- **Inclusion Criteria (n = 157)**
 - Age >18 years
 - On EFV plus ABC-3TC for ≥3 months
 - HIV RNA <50 copies/mL
 - Total cholesterol >200 mg/dL x 2 consecutive tests (at least 4 weeks apart)
 - No resistance to study drugs
- **Treatment Arms**
 - Efavirenz-tenofovir DF-emtricitabine
 - Efavirenz plus abacavir-lamivudine x 12 weeks, then efavirenz-tenofovir DF-emtricitabine

Immediate switch arm

EFV-TDF-FTC

(n = 79)

Delayed switch arm


**EFV + ABC-3TC x 12 weeks,
then EFV-TDF-FTC**

(n = 78)

Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Result


Week 12: Virologic Response (Intent-to-Treat Analysis)



Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Result

Week 12: Changes in Lipid Fractions (Treated Analysis Set)




Baseline for Delayed switch arm was reset at week 12 (prior to switch to EFV-TDF-FTC)

Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Result

Fasting Total Cholesterol by NCEP Thresholds




Patients in Immediate Switch Arm

Source: Moyle GJ, et al. PLoS One. 2015;10:e0116297.

Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Result

Fasting Total Cholesterol by NCEP Thresholds




Source: Moyle GJ, et al. PLoS One. 2015;10:e0116297.

Switch from EFV + ABC-3TC to EFV-TDF-FTC

ROCKET-1: Result

Fasting Total Cholesterol by NCEP Thresholds



Switch from EFV + ABC-3TC to EFV-FTC-TDF

ROCKET-1: Conclusions

Interpretation: “Switching from ABC/3TC+EFV to EFV/FTC/TDF in persons with hypercholesterolemia maintains virological control and significantly improves key lipid parameters.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

